Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment.

In some cell lines and tumors of mammary origin, tamoxifen causes an increase of progesterone receptor (PR) as a result of its partial estrogen agonist activity. In this study we have assessed the effect of tamoxifen on PR in patients with advanced carcinoma of the breast in order to test if those with a rise in PR are more likely to respond to endocrine therapy. PR was measured before and a median of 13 days after treatment with tamoxifen in a group of 52 patients with either locally advanced (n = 28) or recurrent (n = 24) carcinoma of the breast. Controls were a group of patients with operable disease who had two biopsies with no intervening tamoxifen (n = 51) or with intervening tamoxifen (n = 58). In the test group PR was higher in the second biopsy than the first in 21 patients, and 19 of these responded to continued endocrine therapy (90%). In the remaining 31 patients PR was either lower in the second biopsy (n = 19) or was negative in both biopsies (n = 12), and 11 of the total of 31 patients (35%) responded to continued endocrine therapy. The prediction of response and time to progression was better when both biopsies were taken into account than either the first or the second alone. The prediction of survival was similar for the group selected by an increase in the second biopsy and the group with PR present in the second biopsy. The controls without tamoxifen showed a marked variation in the level of PR in the first and second biopsies, suggesting heterogeneity of PR across the tumors studied. However, the PR level was significantly higher in the second biopsy in the controls given tamoxifen and in the test group compared with those with no intervening treatment (p = 0.031). This study indicates that some effect of tamoxifen upon PR can be demonstrated in human mammary tumors in vivo and that, by taking a second biopsy for PR estimation during treatment with tamoxifen, a more precise indication of subsequent response is obtained. The value of a single estimation of PR before treatment on secondary deposits is limited, and if one biopsy only is performed, it is of greater predictive value if taken after a few days treatment with tamoxifen.

[1]  W. McGuire,et al.  Quantitative enzyme-linked immunosorbent assay for the estrogen-regulated Mr 24,000 protein in human breast tumors: correlation with estrogen and progesterone receptors. , 1985, Cancer research.

[2]  M. Lippman,et al.  Relationship between the expression of estrogen-regulated genes and estrogen-stimulated proliferation of MCF-7 mammary tumor cells. , 1985, Cancer research.

[3]  M. Le Cunff,et al.  Cloning of a gene expressed in human breast cancer and regulated by estrogen in MCF-7 cells. , 1985, DNA.

[4]  P. Chambon,et al.  Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. Pau,et al.  Immunohistochemical detection of the estrogen-regulated 52,000 mol wt protein in primary breast cancers but not in normal breast and uterus. , 1984, The Journal of clinical endocrinology and metabolism.

[6]  M. Dietel,et al.  In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. , 1984, Journal of the National Cancer Institute.

[7]  R. Cardiff,et al.  A monoclonal antibody to a human breast tumor protein released in response to estrogen. , 1984, Cancer research.

[8]  M. Lippman,et al.  Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells. , 1984, Cancer research.

[9]  W. McGuire,et al.  The prognostic role of progesterone receptors in human breast cancer. , 1983, Seminars in oncology.

[10]  D. Barnes,et al.  Progesterone receptor measurement by isoelectric focusing: a potential microassay. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[11]  L. G. Skinner,et al.  Isoelectric focusing of oestradiol receptor protein from human mammary carcinoma--a comparison with dextran coated charcoal assay. , 1982, Journal of steroid biochemistry.

[12]  M. Lippman,et al.  Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. , 1981, The Journal of biological chemistry.

[13]  H. Imura,et al.  Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. , 1981, Cancer research.

[14]  N. Bloom,et al.  The value of progesterone receptor assays in the management of advanced breast cancer , 1980, Cancer.

[15]  M. Namer,et al.  Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. , 1980, Cancer research.

[16]  W. McGuire,et al.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. , 1978, Endocrinology.

[17]  D. Barnes,et al.  Two methods for measurement of oestradiol-17 beta and progesterone receptors in human breast cancer and correlation with response treatment. , 1977, European journal of cancer.

[18]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[19]  W. McGuire,et al.  Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1975, Science.

[20]  D. Sutherland.  Plasminogen-activating activity: association with steroid binding by cytosols of human breast cancers. , 1980, Journal of the National Cancer Institute.

[21]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.